Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects

NCT03383042 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Anti-Ulcer Agents

Interventions

DRUG: Cohort 1 (JP-1366 A mg)
DRUG: Cohort 2 (JP-1366 B mg)
DRUG: Cohort 3 (JP-1366 C mg)
DRUG: Cohort 4 (JP-1366 D mg)
DRUG: Cohort 5 (JP-1366 E mg)
DRUG: Cohort 6 (JP-1366 F mg)
DRUG: Cohort 7 (JP-1366 G mg)
DRUG: Cohort 8 (JP-1366 H mg)
DRUG: Cohort 9 (JP-1366 I mg)

Sponsor

Jeil Pharmaceutical Co., Ltd.